🇺🇸 FDA
Patent

US 11932870

Compositions and methods for immune cell modulation in adoptive immunotherapies

granted A61KA61K2239/48A61K31/444

Quick answer

US patent 11932870 (Compositions and methods for immune cell modulation in adoptive immunotherapies) held by Fate Therapeutics, Inc. expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Fate Therapeutics, Inc.
Grant date
Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2239/48, A61K31/444, A61K31/519, A61K39/39558